Abstract

Micropeptides (miPEPs), or peptides coded by microRNAs, for promoting nodulation between a plant and a bacterium, as well as their use in this manner.

IPC Classes  ?

• A01H 17/00 - Symbiotic or parasitic combinations including one or more new plants, e.g. mycorrhiza
• A01N 65/20 - Fabaceae or Leguminosae [Pea or Legume family], e.g. pea, lentil, soybean, clover, acacia, honey locust, derris or millettia
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• C12N 1/20 - BacteriaCulture media therefor
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells

Abstract

The present invention relates to hydrosilylation reactions between a monosubstituted alkene compound and a compound comprising at least one hydrogen atom bonded to a silicon atom. More specifically, the invention relates to a process for the hydrosilylation of an unsaturated compound (A) that comprises at least one monosubstituted alkene function with a compound (B) that comprises at least one hydrosilane function, said process comprising the step of exposing said unsaturated compound (A) and said compound (B) to irradiation in the presence of a photocatalyst (C) consisting of a manganese carbonyl. This hydrosilylation reaction between an alkene compound and a compound comprising at least one hydrogen atom bonded to a silicon atom makes it possible, in particular, to cure silicone compositions by crosslinking.

IPC Classes  ?

• C07F 7/08 - Compounds having one or more C—Si linkages
• B01J 23/34 - Manganese

Abstract

The present invention relates to a process and a system for the production of hydrogen and carbon by catalytic non-oxidative decomposition of hydrocarbons, such as saturated C1+ hydrocarbons, such as methane, in the presence of a fresh or a spent catalyst composition comprising at least one carbon catalyst. The process of the invention is characterised in that the fresh or spent catalyst composition is heated by means of induction heating to a temperature comprised between 500° C. and 1100° C. The catalyst compositions as applied in accordance with the invention comprise, and preferably consist of, (I) a first component, wherein said first component is selected from one or more non-porous carbon catalysts and/or one or more porous carbon catalysts; and (II) optionally, a second component, wherein said second component consists of a non-carbon material, and preferably is a ceramic or zeolitic support material. Further provided are a spent catalyst obtained when carrying out a process of the invention, and uses thereof.

IPC Classes  ?

• C01B 3/26 - Production of hydrogen or of gaseous mixtures containing hydrogen by decomposition of gaseous or liquid organic compounds of hydrocarbons using catalysts
• C01B 32/05 - Preparation or purification of carbon not covered by groups , , ,

Abstract

The present disclosure relates to methods for treating infectious disorders. In particular, the disclosure provides BTN3A activating antibodies, and their use in treating infectious disorders in a human subject in need thereof, such as disorders caused by SARS-Cov2 or Coxiella burnetii infection.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 31/04 - Antibacterial agents
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The present invention relates to a population of small extracellular vesicles (sEVs) for use in the treatment of obesity in a subject in need thereof, wherein the sEVs comprise at least one polynucleotide encoding a D168A dominant negative AMP-activated protein kinase alpha 1 (AMPKa1-DN) mutant protein operably linked and under the control of a steroidogenic factor 1 (SF1) promoter, wherein the sEVs are engineered to transiently express in their outer membrane at least one fusion protein comprising the neurotrophic rabies virus (RVG) peptide fused to lysosome-associated membrane protein 2b. Said population is highly safe and effective, as the sEVs, when administered systematically, are capable of exerting their effect in the SF1 expressing neurons located in the ventromedial nucleus of the hypothalamus.

IPC Classes  ?

• A61K 38/45 - Transferases (2)
• A61K 9/50 - Microcapsules
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61P 3/04 - AnorexiantsAntiobesity agents

Abstract

A computer-implemented method for training a multi-task network having at least one recurrent network has task-specific cells, respectively blocks of tasks, a differentiable order selector for determining a convex combination of a number M of different possible task orders, respectively blocks orders, for processing an input, by allocating a selector order coefficient πi to each task order, respectively block order; and, a merging module for computing the weighted average of the outputs given by the recurrent network for the M orders using as weights the order selector coefficients (π1, π2, . . . , πM). The method includes training jointly the task-specific cells and the order selector to minimize a loss function.

IPC Classes  ?

• G06N 3/044 - Recurrent networks, e.g. Hopfield networks
• G06N 3/047 - Probabilistic or stochastic networks
• G06N 3/084 - Backpropagation, e.g. using gradient descent

Abstract

Multiplex CARS microscopy device for analysing a sample (Ech) comprising: -a laser source (LS) suitable for emitting a primary beam (FP) having a first wavelength λ1, in the form of pulses (IL1) with a power called the primary power; -an optical fibre (F) supporting fewer than ten modes, said pulses propagating through the optical fibre (F) in anomalous dispersion regime so as to generate, from the primary beam, an output beam (FSC) containing a plurality of second wavelengths forming a supercontinuum (SC), and said first wavelength λ1, the second wavelengths being generated by non-linear conversion of the first wavelength λ; -an optical system (MO) suitable for focusing the output beam onto said sample, so as to generate an anti-Stokes beam (STK) via stimulated Raman scattering induced by at least one of the second wavelengths and the first wavelength λ1 present in the output beam; -a photodetector (Det) suitable for detecting the anti-Stokes beam.

IPC Classes  ?

• G01N 21/65 - Raman scattering
• G02F 1/35 - Non-linear optics

Abstract

A magnet assembly for an electrodynamic loudspeaker driver, comprising a first outer pair of axially magnetized, permanent ring magnets, having a first thickness and a second inner pair of axially magnetized, permanent ring magnets, having a second thickness less than the first thickness, the face of the first inner magnet facing the second inner magnet being offset by a predefined offset distance (Δy) relative to the face of the first outer magnet facing the second outer magnet, and the face of the second inner magnet facing the first inner magnet being offset by the predefined offset distance (Δy) relative to the face of the second outer magnet facing the first outer magnet.

IPC Classes  ?

• H04R 9/02 - Transducers of moving-coil, moving-strip, or moving-wire type Details
• H04R 7/16 - Mounting or tensioning of diaphragms or cones

Abstract

The present invention relates to a treatment of CCHFV infection, in particular CCFHV infection. Here, the inventors showed that antibody blocking LDL-R family at the surface of human cells could reduce CCHFV infection by 80%, such inhibition only occurred when blocking was performed prior to or at the time of infection though not at later time points. Furthermore, they found that incubation of viral particles with a soluble form of LDL-R could impair CCHFV infection. They found that ApoE antibodies could block CCHFV infectivity by up to 10-fold only when the viral particles were produced in cells that express ApoE. Thus, the present invention relates to an LDL-R family and/or an ApoE inhibitor for use in the prevention and/or the treatment of CCHFV infection in subjects in need thereof.

IPC Classes  ?

• A61K 31/4748 - QuinolinesIsoquinolines forming part of bridged ring systems
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The invention concerns new oncolytic viruses and their uses In particular, the invention is a viral particle for its use in the prevention and/or the treatment of a tumor, said viral particle comprising: an inactivated nucleic acid sequence encoding the native envelope glycoprotein of the IROV encoded by said IROV genome; and a nucleic acid sequence encoding a retroviral envelope glycoprotein or a fragment thereof having a native targeting capacity for said host cell surface protein.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C12N 15/86 - Viral vectors
• A61P 35/00 - Antineoplastic agents
• A61K 35/766 - Rhabdovirus, e.g. vesicular stomatitis virus

Abstract

The invention relates to an oligo-initiator, to the process for synthesizing same and to the use thereof for producing water-soluble hybrid polymers. It also relates to a water-soluble hybrid polymer obtained according to a synthesis process comprising the functionalization of a biopolymer by reacting its functional groups with the functional groups of the oligo-initiator, allowing the extension of synthetic polymer chains, thus forming said water-soluble hybrid polymer. The invention also relates to the use of the water-soluble hybrid polymer in various fields of application.

IPC Classes  ?

• C08F 2/38 - Polymerisation using regulators, e.g. chain terminating agents
• C08G 81/02 - Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers at least one of the polymers being obtained by reactions involving only carbon-to-carbon unsaturated bonds
• C08F 293/00 - Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule

Abstract

The invention concerns a method for fabricating an array of magnets (10), the method comprising: - a step of deposition of a coercivity changing element according to a pattern on a first material having a first coercivity value, the coercivity changing element being adapted to change the coercivity of the first material, and - a step of diffusion of the coercivity changing element into certain regions to form a magnetic layer (16) having first areas (A1) made of the first material and second areas (A2) having a second coercivity, made of a second material comprising the first material and the coercivity changing element.

IPC Classes  ?

• H01F 7/02 - Permanent magnets
• H01F 1/032 - Magnets or magnetic bodies characterised by the magnetic materials thereforSelection of materials for their magnetic properties of inorganic materials characterised by their coercivity of hard-magnetic materials
• H01F 41/02 - Apparatus or processes specially adapted for manufacturing or assembling magnets, inductances or transformersApparatus or processes specially adapted for manufacturing materials characterised by their magnetic properties for manufacturing cores, coils or magnets
• H01F 13/00 - Apparatus or processes for magnetising or demagnetising
• H01F 1/00 - Magnets or magnetic bodies characterised by the magnetic materials thereforSelection of materials for their magnetic properties
• H01F 41/18 - Apparatus or processes specially adapted for manufacturing or assembling magnets, inductances or transformersApparatus or processes specially adapted for manufacturing materials characterised by their magnetic properties for applying magnetic films to substrates by cathode sputtering
• H01F 10/12 - Thin magnetic films, e.g. of one-domain structure characterised by magnetic layers characterised by the composition being metals or alloys

Abstract

Compositions for use in the prevention and/or treatment of at least one adverse effect of a chemotherapy in the treatment of cancer are disclosed. The compositions have N-acetylcysteine (NAC) and vitamin B12 and/or a combination of vitamins B1, B2 and B3. Methods of treatment of chemo-induced nociceptive and/or neuropathic pain by administering such compositions are also disclosed.

IPC Classes  ?

• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 31/455 - Nicotinic acid, i.e. niacinDerivatives thereof, e.g. esters, amides
• A61K 31/51 - Thiamines, e.g. vitamin B1
• A61K 31/525 - Isoalloxazines, e.g. riboflavins, vitamin B2
• A61K 31/714 - Cobalamins, e.g. cyanocobalamin, vitamin B12

Abstract

The present disclosure provides Nectin-4 antibody drug conjugates (ADCs) comprising exatecan and pharmaceutical compositions thereof, and methods of using the ADCs for the treatment of cancer.

IPC Classes  ?

• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61P 35/00 - Antineoplastic agents

Abstract

The invention relates to a measurement system (1) and to the associated measurement method, the system comprising an FTIR spectrometer (2) comprising a tracker module (20), a protection device (3) comprising a casing (30) and a protection module (31) movable between a closed position (P0) and at least one open position (P1). For this purpose, the protection module (31) comprises a cover (310) that is rotatable about an axis (A1) parallel to the main extension plane of an upper surface (30a) of the casing (30), so as to move between the closed position (P0) and the at least one open position (P1); and an actuator (311) configured to drive the cover between the closed position (P0) and the at least one open position (P1).

IPC Classes  ?

• G01J 3/02 - SpectrometrySpectrophotometryMonochromatorsMeasuring colours Details
• G01J 3/45 - Interferometric spectrometry

Abstract

The invention relates to a device comprising a voxel structure (11) and a shell (12) that encloses the structure, which, when stacked along a direction, referred to as the stacking direction (z), forms at least a first level (1) and a second level (2), wherein each level comprises a first shell section (121) and a second shell section (122), respectively, wherein each shell section comprises a first cavity (1211) and a second cavity (1222), respectively, wherein each cavity comprises side walls (1211a), and a first set of voxels (111) and a second set of voxels (112), respectively, wherein each set of voxels comprises side faces (113) connecting a first face (114) and a second face (115) that are opposite one another, wherein the first and second cavities accommodate the first and second sets, wherein the side walls of the first and second cavities are configured to hold the side faces of the first and second sets, and wherein the levels are stacked such that the second face of the first set and the first face of the second set are at least partially in contact and form a one-piece structure.

IPC Classes  ?

• B29C 64/10 - Processes of additive manufacturing
• B22F 12/00 - Apparatus or devices specially adapted for additive manufacturingAuxiliary means for additive manufacturingCombinations of additive manufacturing apparatus or devices with other processing apparatus or devices
• B29C 64/30 - Auxiliary operations or equipment
• B33Y 40/00 - Auxiliary operations or equipment, e.g. for material handling
• B33Y 80/00 - Products made by additive manufacturing

Abstract

The present invention concerns bichromophoric compounds and methods of preparation thereof. Said invention also concerns the uses of these compounds, notably in the study of metallo-biomedical agents, notably metallo-pharmaceuticals or metallo-contrast agents, in particular for the study of the biotransformations of metallo-biomedical agents, notably metallo-pharmaceuticals or metallo-contrast agents, more particularly to localize and/or quantify in vitro or in vivo the biotransformations of metallo-biomedical agents, notably metallo-pharmaceuticals or metallo-contrast agents.

IPC Classes  ?

• C09B 57/02 - Coumarine dyes
• C09B 57/10 - Metal complexes of organic compounds not being dyes in uncomplexed form

Abstract

H22 HH +ee -, formula 1. The at least one first electrode comprises at least one redox couple My/Mx, insoluble in the electrolytic media, said at least one redox couple being arranged to exhibit at least two oxidation states and being suitable to be reduced from an oxidized state Myto a reduced state MxMM ypMM x, formula 2, wherein x and y are oxidation number. An absolute potential difference | ΔE | between a redox potential of the couple H+22, for a predetermined electrolytic media and a predetermined pressure range of gaseous dihydrogen, and a redox potential of the at least one couple My/Mx is lower than or equal to 0.6 V.

IPC Classes  ?

• C25B 15/08 - Supplying or removing reactants or electrolytesRegeneration of electrolytes
• H01M 8/0656 - Combination of fuel cells with means for production of reactants or for treatment of residues with means for production of gaseous reactants by electrochemical means
• C01B 3/00 - HydrogenGaseous mixtures containing hydrogenSeparation of hydrogen from mixtures containing itPurification of hydrogen
• C25B 1/02 - Hydrogen or oxygen
• C25B 1/50 - Processes
• C25B 11/081 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of a single catalytic element or catalytic compound the element being a noble metal
• C25B 11/085 - Organic compound
• C25B 11/089 - Alloys

Abstract

The invention relates to a photovoltaic module (10) with integrated connections for assembly in series and in parallel, comprising a substrate (1) and a plurality of photovoltaic cells (2) which are identical and carried together by one face of the substrate, each photovoltaic cell being formed by a relevant portion of a single stack of layers of solid materials. The photovoltaic module further comprises portions of electrically conductive layers, which are carried by the substrate (1) and arranged to electrically connect the photovoltaic cells (2) according to a combination of at least one assembly in parallel with at least one assembly in series. Such a photovoltaic module is particularly suitable for forming part of a composite photovoltaic panel operating in tandem.

IPC Classes  ?

• H01L 31/046 - PV modules composed of a plurality of thin film solar cells deposited on the same substrate

Abstract

The invention relates to a device (2, 4) for homogenizing a radiofrequency field, for magnetic resonance imaging, of a given wavelength emitted by a volumetric antenna, comprising at least one continuous metal track (8) with a total length of between 50% and 75% of the wavelength of the radiofrequency field, the metal track comprising two end segments extending in mutually parallel directions and a main portion extending between the two end segments and comprising several local deformations identical to one another and connected to one another in series by at least one at least partially rectilinear connection portion (14) in such a way as to provide the homogenizing device (2, 4) with an electric dipole property, the homogenizing device having a fundamental frequency higher than the frequency corresponding to the wavelength of the radiofrequency field.

IPC Classes  ?

• G01R 33/34 - Constructional details, e.g. resonators
• G01R 33/565 - Correction of image distortions, e.g. due to magnetic field inhomogeneities

Abstract

A composition comprising K2CO3, KCl, and optionally K2SO4 and/or KHCO3, having a weight content of potassium between 9.0 and 60.0% relative to the total weight of the composition, preferably between 10.0 and 50.0%, more preferably between 10.0 and 40.0%, advantageously between 20.0 and 40.0%.

IPC Classes  ?

• B01J 27/232 - Carbonates
• B01J 37/08 - Heat treatment
• B01J 37/36 - Biochemical methods
• C07C 67/32 - Decarboxylation

Abstract

The present invention relates to a non-invasive prognostic method for assessing the prognostic of atrial cardiomyopathy in a subject in need thereof comprising determining a prognostic score based on groove epicardial adipose tissue variables and at least one additional demographic, metabolic or biologic variable. The present invention further relates to a method for preventing atrial cardiomyopathy occurrence in a subject, comprising determining the personalized course of the personalized course of clinical follow-up and/or preventive medical care for the subject based on the obtained prognostic score.

IPC Classes  ?

• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
• G16H 30/00 - ICT specially adapted for the handling or processing of medical images

Abstract

Compositions related to recycled materials, optionally post-consumer/post-industrial polymeric materials (PC/IPM) and related methods, are generally described. The compositions may include a copolyester product from a transesterification reaction comprising crystallizable polymers or copolymers, of which at least one is present in a PC/IPM. The copolyester product may comprise heterolinkage dyads centered on diacid residue. Related methods may include combining crystallizable polymers or copolymers to form a mixture and subjecting the mixture to a temperature and/or stress to produce a copolyester product from a transesterification reaction.

IPC Classes  ?

• C08G 81/00 - Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
• C08G 63/183 - Terephthalic acids
• C08G 63/91 - Polymers modified by chemical after-treatment
• C08J 11/04 - Recovery or working-up of waste materials of polymers
• C08J 11/10 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation
• C08J 11/18 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation by treatment with organic material

Abstract

The invention relates to a set of luminescent light concentrators for wide-spectrum emission, the set being intended to be pumped by pump radiation having a pump wavelength and comprising: - a first luminescent light concentrator (C1), the first concentrator being made of a first material suitable for absorbing the pump radiation and then emitting first luminescent radiation (L1) having a first central emission wavelength within the first concentrator, - a second luminescent light concentrator, contiguous to the first concentrator, made of a second material suitable for absorbing the pump radiation and then emitting second luminescent radiation (L2) having a second central emission wavelength longer than the first wavelength within the second concentrator, - a third luminescent light concentrator, contiguous to the second concentrator, made of a third material suitable for absorbing the pump radiation and then emitting third luminescent radiation (L3) having a third central emission wavelength longer than the second wavelength within the third concentrator, such that the set of concentrators is suitable for emitting, through a first exit face, an output light emission containing the first, second and third central emission wavelengths and formed from a portion of each of the first luminescent radiation, second luminescent radiation and third luminescent radiation when the first, second and third luminescent light concentrators all absorb the pump radiation.

IPC Classes  ?

• F21V 8/00 - Use of light guides, e.g. fibre optic devices, in lighting devices or systems
• F21K 9/61 - Optical arrangements integrated in the light source, e.g. for improving the colour rendering index or the light extraction using light guides
• F21K 9/64 - Optical arrangements integrated in the light source, e.g. for improving the colour rendering index or the light extraction using wavelength conversion means distinct or spaced from the light-generating element, e.g. a remote phosphor layer
• F21V 9/32 - Elements containing photoluminescent material distinct from or spaced from the light source characterised by the arrangement of the photoluminescent material
• F21V 9/38 - Combination of two or more photoluminescent elements of different materials
• G03B 21/20 - Lamp housings
• G02B 19/00 - Condensers
• H01S 3/04 - Arrangements for thermal management
• H01S 3/08 - Construction or shape of optical resonators or components thereof
• H01S 3/094 - Processes or apparatus for excitation, e.g. pumping using optical pumping by coherent light

Abstract

Clk1Pak1Clk-4Pak1Pak1 using validated shRNAs and combinations of FRAX597 and TG003, or FRAX597 and ML 167 synergized to reduce the growth and the colony-forming capacity of chemoresistant AML cells and sensitized them to chemotherapy. The combined treatment improved overall mouse survival and reduced disease burden in the chemoresistant AML mouse models. Moreover, AML patient cells that were primarily refractory or from a post chemotherapy relapse (n=21 ) exhibited a higher ex vivo sensitivity to the FRAX597 + TG003 combination in comparison with chemosensitive patients at diagnosis (n=28). Finally, combined PAK1 and CLK inhibition more effectively reduced disease progression in animals transplanted with the relapse sample than in those engrafted with the sample taken at diagnosis. Thus, the present invention relates to combination of PAK1 inhibitors and CLK inhibitors for preventing resistance to chemotherapy in patients suffering from acute myeloid leukemia.

IPC Classes  ?

• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/02 - Antineoplastic agents specific for leukemia

Abstract

Method for controlling the motion of a target drone Method (100) for controlling a motion of a target drone (4) inside a geographical area of interest (Z), comprising the steps of : - acquisition (110), by a plurality of measuring devices located throughout the geographical area of interest, of a plurality of measures of values of wind parameters, the wind parameters comprising an amplitude and an orientation of the wind; - determining (130), from the plurality of measures, boundary conditions, defined as values of the wind parameters at a boundary of a domain surrounding the geographical area of interest; - determining (140), by using a first parametric function that depends on the boundary conditions only, a wind field, the wind field providing the values of the wind parameters in any point inside the domain; and, - controlling (160) the target drone by taking into account the wind field.

IPC Classes  ?

• G05D 1/606 - Compensating for or utilising external environmental conditions, e.g. wind or water currents
• G05D 105/22 - Specific applications of the controlled vehicles for transportation of humans
• G05D 107/17 - Spaces with priority for humans, e.g. populated areas, pedestrian ways, parks or beaches
• G05D 109/25 - Rotorcrafts

Abstract

The invention relates to a method for producing a crystalline tellurate comprising at least zinc; the method comprising the following steps: providing a cationic aqueous solution comprising Zn2+and Te6+ cations; co-precipitating the crystalline tellurate in liquid medium by applying a pH to the cationic aqueous solution, the pH being maintained at a value ranging from 5.00 to 10.00; and optionally separating the crystalline tellurate from the liquid medium.

IPC Classes  ?

• C01B 19/00 - SeleniumTelluriumCompounds thereof

Abstract

OF THE INVENTION LOCAL ADMINISTRATION OF RIPK2 INHIBITORS FOR THE CURATIVE TREATMENT OF ALLERGIC ASTHMA The present invention relates to a method for use in the treatment of Asthma. Here, the inventors identified the receptor-interacting serine/threonione protein kinas 2 (RIPK2) as a novel therapeutic target to improve Asthma-related diseases. They demonstrated that a local preventive administration of the RIPK2 inhibitor reduced AHR, airway eosinophilia, mucus production, Th2 cytokines and the alarmin IL-33. Moreover, they demonstrated the early role of IL-33 in the NOD1-dependent response of the epithelium to HDM. Therefore, the inventors demonstrated that the local interference of the NOD1 signaling pathway through RIPK2 inhibition may represent a new therapeutic approach in asthma. Other pulmonary diseases could also benefit of this treatment. Thus, the present invention relates to a method for use in the curative treatment of HDM-induced asthma comprising administrating to a subject in need thereof a therapeutically effective amount of an inhibitor of RIPK2.

IPC Classes  ?

• A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
• A61K 31/47 - QuinolinesIsoquinolines
• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 11/06 - Antiasthmatics
• A61P 37/08 - Antiallergic agents

Abstract

The invention relates to a method implemented by computer means for quantifying irregularities of a surface of an anatomical region of a patient in at least one medical image, said method comprising the following steps: (a) obtaining at least one medical image representing said anatomical region, (b) segmenting said anatomical region or at least a part of said anatomical region, (c) detecting the actual contour of said anatomical region from said segmented anatomical region, (d) computing a smoothed contour of said anatomical region based on said actual contour, (e) calculating a score based on the distance between the actual contour and the smoothed contour.

IPC Classes  ?

• G06T 7/00 - Image analysis
• G06T 7/12 - Edge-based segmentation

Abstract

The present invention relates to tetramolecular parallel G-quadruplex-forming oligonucleotides. If G-quadruplexes are of prime importance in biology, their use is hampered by the propensity of G4-prone DNA molecules, in particular G4-prone DNA molecules of long size, to adopt many different G4 topological conformations or other alternative foldings. By introducing a lipid modification at the end of the oligonucleotide, the inventors succeeded in obtaining long tetramolecular parallel G-quadruplexes (tpG4). The present invention thus concerns an oligonucleotide modified by substitution at the 5′ or the 3′ end by a lipid moiety, wherein said oligonucleotide comprises a nucleic acid sequence of at least 10 nucleotides, said nucleic acid sequence including a series of at least 4 consecutive guanine residues located in the middle of said sequence. A tetramolecular parallel G-quadruplex comprising 4 identical modified oligonucleotides as defined above, wherein each of the 4 consecutive guanine residues included in the middle of the nucleic acid sequence of each oligonucleotide respectively form G-quartets with the corresponding guanine residues of the other 3 oligonucleotides, said G-quartets being stabilized by π-π staking and Hoogsteen hydrogen bonding, is also contemplated.

IPC Classes  ?

• C12N 15/11 - DNA or RNA fragmentsModified forms thereof

Abstract

Here, the Inventors show that chronic IL- 1 -induced H2A.X signaling, which mediated DNA DSB response, in hippocampal neurons is a critical driver of cognitive deficits in chronic low grade neuroinflammation. They show that mice chronically infected with the brain- persisting T. gondii parasite display deficits in spatial memory consolidation without general memory loss. Extensive mapping of the neuroinflammatory landscape, beyond a latent T. gondii infection elicited type 1-like neuroinflammation, display elevated production of IL-1α and IL-1β in the hippocampus. Using a mouse model to specifically delete the IL-1 receptor from excitatory neurons, they uncovered that neuronal IL-1 signaling is required for the spatial memory deficits caused by latent T. gondii infection. By singling out a chronic exposure to IL- ip they found that IL-1β signaling in neurons indeed impairs spatial memory. Moreover, they showed that chronic exposure to IL-1β increases DNA DSB levels in neurons, and that neuronal H2A.X-dependent DSB response mediates the IL-1β-induced memory deficits. Importantly, neuronal DSBs were also increased upon T. gondii infection and the deficit in hippocampus- dependent spatial memory caused by T. gondii infection was prevented by the abrogation of neuronal H2A.Xdependent signaling. These results highlight the instrumental role of cytokine- induced DSB-dependent signaling in spatial memory defects elicited by a chronic infectious neuroinflammatory process. Accordingly, the present invention relates to a method of treating a subject suffering from cognitive deficit comprising administering to said subject a therapeutically effective amount of an inhibitor of IL- 1 -induced H2A.X signaling.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The invention relates to an electrochlorination electrode (1) and to the related manufacturing method, the electrode comprising an electrically conductive substrate (10), at least one catalytic layer (11) comprising metal and metalloid chemical elements, characterised in that the at least one catalytic layer (11) comprises ruthenium with a mass proportion of between 10% and 40%, titanium with a mass proportion of between 40% and 79%, and boron with a mass proportion of between 1% and 20%, the mass proportions being given relative to the total mass of the metal and metalloid elements in the at least one catalytic layer (11).

IPC Classes  ?

• C02F 1/461 - Treatment of water, waste water, or sewage by electrochemical methods by electrolysis
• C02F 1/467 - Treatment of water, waste water, or sewage by electrochemical methods by electrolysis by electrochemical disinfection
• C25B 1/26 - ChlorineCompounds thereof
• C25B 11/053 - Electrodes comprising one or more electrocatalytic coatings on a substrate characterised by multilayer electrocatalytic coatings
• C25B 11/093 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of at least one catalytic element and at least one catalytic compoundElectrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of two or more catalytic elements or catalytic compounds at least one noble metal or noble metal oxide and at least one non-noble metal oxide

Abstract

1 235621011777 represents a functional group selected among a hydrogen and an aliphatic chain; or a pharmaceutical acceptable derivative thereof, for use as a medicament.

IPC Classes  ?

• C07F 5/02 - Boron compounds
• A61K 31/69 - Boron compounds
• A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys

Abstract

NOMA uplink communications via Reconfigurable Intelligent surfaces are proposed based on the determination of Reconfigurable Intelligent surfaces sub-surface configurations compatible with NOMA successive interference cancellation requirements. For multiple sets of RIS sub-surfaces, the solution extends to reconfiguring user device to sub-channel attributions either in a coordinated mode or an uncoordinated mode based on a multi-player Multi- armed Bandit framework with zero-reward.

IPC Classes  ?

• H04B 7/04 - Diversity systemsMulti-antenna systems, i.e. transmission or reception using multiple antennas using two or more spaced independent antennas
• H01Q 15/14 - Reflecting surfacesEquivalent structures
• H04B 7/06 - Diversity systemsMulti-antenna systems, i.e. transmission or reception using multiple antennas using two or more spaced independent antennas at the transmitting station
• H01Q 1/24 - SupportsMounting means by structural association with other equipment or articles with receiving set
• H01Q 3/44 - Arrangements for changing or varying the orientation or the shape of the directional pattern of the waves radiated from an antenna or antenna system varying the electric or magnetic characteristics of reflecting, refracting, or diffracting devices associated with the radiating element
• H01Q 21/28 - Combinations of substantially independent non-interacting antenna units or systems

Abstract

The invention relates to an actuator (1), comprising: at least two elongated deformable lumens (2), each lumen being connectable to a source of a fluid; and a fibre (4) wound around the at least two lumens, wherein the fibre surrounds a whole circumference of each of the at least two lumens over at least part of a length of each of the at least two lumens.

IPC Classes  ?

• F15B 15/10 - Fluid-actuated devices for displacing a member from one position to anotherGearing associated therewith characterised by the construction of the motor unit the motor being of diaphragm type
• B25J 9/14 - Programme-controlled manipulators characterised by positioning means for manipulator elements fluid

Abstract

The present invention relates to an energy storage device (MCLk) comprising an energy storage element (CLk) supplying a voltage (Vclk) and a main switching circuit (COMk) forming an H-bridge the states of which are selectively controllable, the energy storage element (CLk) being able to deliver to connection terminals, in a first state, the voltage (Vclk), in a second state, the voltage inverted and, in a third state, a zero voltage configuring the storage device (MCLk) into a bypass state, bypassing the storage element (CLk), and further comprising a secondary bypass circuit (CCk) for bypassing the main switching circuit (COMk) electrically connected to the first and second connection terminals (S1, S2), able to configure a redundant fourth state bypassing the main switching circuit (COMk).

IPC Classes  ?

• H02M 1/32 - Means for protecting converters other than by automatic disconnection
• H02M 7/49 - Combination of the output voltage waveforms of a plurality of converters

Abstract

221612051423456789212051414 aryl group. The invention also relates to a method for preparing this composite material, to its use, to a kit for its preparation, and to a method for insulating a stator of an electric motor using this composite material. Finally, the invention relates to a non-crosslinked mixture of an epoxy resin comprising thermally conductive fillers and 4,4'-dithiodianiline, the content of thermally conductive filler being between 70% and 90% by weight relative to the total weight of the mixture.

IPC Classes  ?

• C08G 59/50 - Amines

Abstract

The invention relates to a method (10) for manufacturing a metal powder of an alloy reinforced with a ceramic nanoparticle dispersion, comprising spherical metal particles that form a metal matrix and ceramic nanoparticles distributed in the metal matrix, wherein the method comprises: introducing a precursor alloy metal powder intended to form the metal matrix into a fluidisation chamber of a fluidised bed reactor (E1); injecting at least one fluidisation gas into the fluidisation chamber at an injection flow rate that is defined so that the powder particles are suspended due to the drag force exerted by the gas in the chamber and are individualised (E2, E3); heating the suspended metal powder particles in the gas stream to a heating temperature and for a heating duration that are defined so as to allow ceramic nanoparticles to form on the surface of the metal particles and inside the metal particles (E4).

IPC Classes  ?

• B22F 1/05 - Metallic powder characterised by the size or surface area of the particles
• B22F 1/065 - Spherical particles
• B22F 1/12 - Metallic powder containing non-metallic particles
• B22F 1/142 - Thermal or thermo-mechanical treatment
• B22F 1/18 - Non-metallic particles coated with metal
• B33Y 70/10 - Composites of different types of material, e.g. mixtures of ceramics and polymers or mixtures of metals and biomaterials
• C22C 1/04 - Making non-ferrous alloys by powder metallurgy
• C22C 33/02 - Making ferrous alloys by powder metallurgy
• C22C 32/00 - Non-ferrous alloys containing at least 5% by weight but less than 50% by weight of oxides, carbides, borides, nitrides, silicides or other metal compounds, e.g. oxynitrides, sulfides, whether added as such or formed in situ
• B22F 1/16 - Metallic particles coated with a non-metal
• C22C 19/00 - Alloys based on nickel or cobalt
• C22C 19/05 - Alloys based on nickel or cobalt based on nickel with chromium
• C22C 38/18 - Ferrous alloys, e.g. steel alloys containing chromium

Abstract

Compositions generally related to recycled polymers, copolyester products and related methods, are generally described. The compositions may include copolyester products comprising crystallizable polymers and/or copolymers, which may be present in a post-consumable/post-industrial polymeric material. The copolyester products may have characteristics amenable to enzymatic degradation. In some instances, a polymeric feedstock material can include the copolyester product.

IPC Classes  ?

• C08J 11/10 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation
• C08G 81/00 - Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers

Abstract

A technique for moving various objects such as cells and particles of hydrogel or a compressible material, suspended in a fluid, so as to form a layered structure akin to human organ tissue. A standing sound wave is propagated through the fluid so as to position the cells on a pressure node and the particles on a pressure antinode. As such, the cells have a positive acoustic contrast relative to the fluid, while the particles have a negative acoustic contrast relative to the fluid.

IPC Classes  ?

• C12M 1/00 - Apparatus for enzymology or microbiology
• C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means

Abstract

The application relates to an anti-counterfeiting object manufactured using additive manufacturing by depositing a first electrically insulating material in the fused state. It includes at least one conductor of a second conductive material integrated into the first material, the conductor connecting at least two accessible terminals and having a measurable characteristic resistance between the terminals. The application also relates to a method for authenticating the object.

IPC Classes  ?

• G01N 27/04 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating resistance
• B29C 64/171 - Processes of additive manufacturing specially adapted for manufacturing multiple 3D objects
• B29K 101/12 - Thermoplastic materials
• B29K 507/04 - Carbon
• B33Y 10/00 - Processes of additive manufacturing
• B33Y 80/00 - Products made by additive manufacturing

Abstract

The invention relates to a method for obtaining a layer at least partially made of a nitride (N), first comprising the provision of a stack comprising at least one assembly of pads (1000A1-1000B4) extending from a substrate (100). Each pad comprises at least one creep section (220A1-220A5) and one crystalline section (300A1,300A5) surmounting the creep section (200A1-200A5). Then, a crystallite (510A1-510A5) is epitaxially grown on at least some of said pads until coalescence of the crystallites, so as to form a nitride layer (550A). The pads of the assembly are distributed over the substrate, such that the relative arrangement of the pads of the assembly is such that during the epitaxy of the crystallites, the progressive coalescence of the crystallites is always done between, on the one hand, a crystallite or a plurality of coalesced crystallites and, on the other hand, an isolated crystallite.

IPC Classes  ?

• H01L 21/02 - Manufacture or treatment of semiconductor devices or of parts thereof
• C30B 25/18 - Epitaxial-layer growth characterised by the substrate
• C30B 29/40 - AIIIBV compounds

Abstract

The invention relates to a catalytic system based at least on a borohydrido-neodymocene, a dialkyl magnesium compound and a dialkyl zinc compound. The catalytic system can be used both in the homopolymerization of ethylene and in the copolymerization of ethylene and a 1,3-diene.

IPC Classes  ?

• C08F 4/54 - MetalsMetal hydridesMetallo-organic compoundsUse thereof as catalyst precursors selected from light metals, zinc, cadmium, mercury, copper, silver, gold, boron, gallium, indium, thallium, rare earths, or actinides together with other compounds thereof
• C08F 10/02 - Ethene
• C08F 236/06 - Butadiene

Abstract

The invention relates to a catalytic system based at least on a borohydrido-neodymocene, a dialkyl zinc compound and an organomagnesium halide of formula RB-Mg-X in which RB comprises a benzene ring of which two carbon atoms are substituted, one of the two being substituted by a methyl, an ethyl or an isopropyl or forming a ring with the carbon atom which is its closest neighbour, the second carbon atom being substituted by a methyl, an ethyl or an isopropyl, the magnesium atom being in the ortho position in relation to each of said two carbon atoms, and X is a halogen atom. The catalytic system can be used both in the homopolymerization of ethylene and in the copolymerization of ethylene and a 1,3-diene.

IPC Classes  ?

• C08F 4/54 - MetalsMetal hydridesMetallo-organic compoundsUse thereof as catalyst precursors selected from light metals, zinc, cadmium, mercury, copper, silver, gold, boron, gallium, indium, thallium, rare earths, or actinides together with other compounds thereof
• C08F 10/02 - Ethene
• C08F 8/10 - Acylation
• C08F 236/06 - Butadiene

Abstract

The invention relates to a method for the selective preparation of a polymer bearing a chain-end ketone function, comprising the following steps a) to c): a) conducting a polymerization reaction of ethylene or of a monomer mixture containing ethylene and a 1,3-diene in the presence of a borohydrido-neodymocene, b) conducting a reaction of a zinc dihalide with the reaction product of step a), c) conducting a reaction of an acid halide with the reaction product of step b).

IPC Classes  ?

• C08F 4/54 - MetalsMetal hydridesMetallo-organic compoundsUse thereof as catalyst precursors selected from light metals, zinc, cadmium, mercury, copper, silver, gold, boron, gallium, indium, thallium, rare earths, or actinides together with other compounds thereof
• C08F 10/02 - Ethene
• C08F 8/10 - Acylation
• C08F 236/06 - Butadiene

Abstract

The invention relates to a process for the solid-state alkalinisation of a salt that comprises at least one transition metal and is deficient in an alkali metal, this process being characterised in that it comprises the following steps: a) mixing, in solid form, the salt that is deficient in (or does not comprise) an alkali metal with the corresponding alkali metal iodide, this iodide also being in solid form, to obtain a solid mixture; b) reacting the solid mixture to obtain molecular iodine and a salt of the alkali-metal-enriched transition metal; and, optionally, c) separating the molecular iodine from the solid mixture.

IPC Classes  ?

• C01B 25/45 - Phosphates containing plural metal, or metal and ammonium
• H01M 10/052 - Li-accumulators
• H01M 10/054 - Accumulators with insertion or intercalation of metals other than lithium, e.g. with magnesium or aluminium
• H01M 10/54 - Reclaiming serviceable parts of waste accumulators
• C01G 45/12 - Complex oxides containing manganese and at least one other metal element
• C01G 49/00 - Compounds of iron
• C01G 51/00 - Compounds of cobalt
• C01G 53/00 - Compounds of nickel
• H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
• H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
• H01M 4/58 - Selection of substances as active materials, active masses, active liquids of inorganic compounds other than oxides or hydroxides, e.g. sulfides, selenides, tellurides, halogenides or LiCoFySelection of substances as active materials, active masses, active liquids of polyanionic structures, e.g. phosphates, silicates or borates
• H01M 4/62 - Selection of inactive substances as ingredients for active masses, e.g. binders, fillers

Abstract

The field of devices for the draining urine that are attached to the penis of a patient, in particular a patient with urinary incontinence, without a medical glue or adhesive. The device includes a balanic sheath and an attachment system, wherein the balanic sheath includes a proximal portion, the proximal portion of the balanic sheath having a frustoconical inner surface and an outer surface each having a distal end having a small diameter and a proximal end having a large diameter, wherein the attachment system is configured to hold the retracted foreskin on the outer surface of the proximal portion, the balanic sheath including a distal portion extending the proximal portion with an outer surface having a protrusion, such that the retracted foreskin is held by the attachment system between the proximal portion and the distal portion.

IPC Classes  ?

• A61F 5/453 - Genital receptacles for collecting urine or other discharge from male member

Abstract

Nowadays, the interest to use ultrasound waves in medical field is well established. Such ultrasound waves may be focused for treating a zone in an organ such as the brain for instance. The focus allows to treat only the zone relative to the disease and avoid treating a healthy zone. Therefore, it is mandatory to use an image guidance system to monitor in real time where the ultrasound waves are focused. The guidance can be performed by Magnetic Resonance Imaging (MRI), Ultrasound Imaging (echography), or Optical Imaging (neuronavigation). However, such systems increase the cost and the complexity of the whole process. The present disclosure overcomes the above drawbacks by proposing a self-positioning acoustic lens allowing to ensure good ultrasound waves transmission in the zone to treat without requiring to the use of a navigation system.

IPC Classes  ?

• A61N 7/02 - Localised ultrasound hyperthermia
• A61N 7/00 - Ultrasound therapy

Abstract

Melanoma cell plasticity plays a key role in the acquisition of resistance to therapy. TRIM24/TIF1α, which encodes for the tripartite RING/B-Box/Coil-coiled transcriptional coactivator, is frequently amplified in human melanomas. The inventors observed a strong correlation between elevated TRIM24 expression and metastatic disease, adverse outcome to immune checkpoint inhibitor therapy and a worse relapse-free survival. shRNA-mediated knock-down of TRIM24 decreased the migratory capacities and increased the sensitivity to BRAF inhibitors in two cellular melanoma models. RNA-sequencing analyses revealed that TRIM24 knock-down significantly represses undifferentiated/invasive transcriptional programs. A protac-based approach for degradation of Trim24 was shown to resensitize resistant melanoma cells to BRAF inhibitors. Thus, the present invention relates to a method for predicting the survival time of a patient suffering from melanoma comprising the step of measuring the level of TRIM24, and the use of TRIM24 inhibitor for treating melanoma, in particular resistant melanoma.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

Several gastrointestinal and gynecological malignancies have the potential to disseminate and grow in the peritoneal cavity. The occurrence of peritoneal carcinomatosis (PC) has been shown to significantly decrease overall survival in patients. Treatment of residual microscopic disease remains a challenge with new anticancer modalities development. Now, the inventors propose an innovative therapeutic management of peritoneal carcinomatosis (PC) that is bio-inspired and tumor-targeted by combining MSC-derived EVs and at least one chemotherapeutic agent for improved chemotherapy efficiency ty. In this work, the present inventors have shown in two different mice models of PC and with two different chemotherapeutic agents that, while the MSC-derived EVs from mice (mEVs) have no effect on mice suffering from PC, treatment with mEvs combined with chemotherapeutic agent has a superior therapeutic effect i.e. a significant reduction of the Peritonal Carcinomatosis Index (PCI) compared to treatment with chemotherapeutic agent alone. Thus, the present invention relates to the combination of EVs and at least one chemotherapeutic agent and uses thereof for the treatment of cancers such as PC.

IPC Classes  ?

• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61K 31/282 - Platinum compounds
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/555 - Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents

Abstract

xy oxyzz along the Z-axis, the specific zone (115) being located in a core of the solenoid (113).

IPC Classes  ?

• B29C 64/106 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material
• B22F 10/12 - Formation of a green body by photopolymerisation, e.g. stereolithography [SLA] or digital light processing [DLP]
• B29C 64/124 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using layers of liquid which are selectively solidified
• B29C 64/20 - Apparatus for additive manufacturingDetails thereof or accessories therefor
• B29C 64/241 - Driving means for rotary motion
• B29C 64/30 - Auxiliary operations or equipment
• B33Y 10/00 - Processes of additive manufacturing
• B33Y 30/00 - Apparatus for additive manufacturingDetails thereof or accessories therefor
• B33Y 70/10 - Composites of different types of material, e.g. mixtures of ceramics and polymers or mixtures of metals and biomaterials
• H01F 7/02 - Permanent magnets
• H01F 7/20 - ElectromagnetsActuators including electromagnets without armatures
• H01F 41/02 - Apparatus or processes specially adapted for manufacturing or assembling magnets, inductances or transformersApparatus or processes specially adapted for manufacturing materials characterised by their magnetic properties for manufacturing cores, coils or magnets

Abstract

The present invention relates to a method to capture circulating tumor extracellular vesicles. Here the inventors describe a novel approach inspired by Chimeric Antigen Recognition (CAR)-like strategy, to selectively capture and locally accumulate circulating tumor EVs towards engrafted trapping cells, or endogenous trapping tissues of choice. Focusing on Prostate Cancer (PCa)-derived EVs as a proof of concept, they combined the pHluorin- genetic tagging of tumor EVs with the expression on target cells of the EV-Trap, a chimeric surface mCD8α receptor exposing various nanobodies directed against EVs' surface antigens (synthetic or tumor associated). They demonstrate how the simultaneous presence of PCa- derived CD63-pHluorin+, CD9-pHluorin+ or PSMA+ EVs in a system presenting GFP-TRAP or PSMA-TRAP accessible cell surfaces, results in significant accumulation and rerouting of PCa-derived pHluorin and PSMA EVs towards the EV-TRAP sites, both in vitro and in vivo in the zebrafish embryo. This approach has the potential to shed new lights on the role of EVs in various physiopathological processes, in particular on pre-metastatic niches formation. Thus, the present invention relates to a fusion protein comprising or consisting of an antigen binding compound, the mCD8α and optionally a domain which induce endocytosis (or internalisation).

IPC Classes  ?

• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 35/00 - Antineoplastic agents
• C12N 15/62 - DNA sequences coding for fusion proteins

Abstract

The present invention relates to an optomechanical microwave clock (100, 300, 400) integrated on a chip (103), comprising: - an optical waveguide (102) arranged on the chip (103),5 - a nano-cavity (101) arranged substantially parallel to the optical waveguide (102), wherein a modulation frequency of an optical mode excited in the nano-cavity (101) corresponds to an oscillation frequency of a mechanical mode of the nano-cavity (101), the modulated optical mode being evanescently coupled 10 to the optical waveguide (102) in at least one coupling region; wherein the optomechanical clock (100, 300, 400) further comprises: - mode-lock means configured to control the optomechanical oscillation stability of the optomechanical microwave clock, the mode-lock means comprising at least one of:15  contact-free radio-frequency mode-lock means,  acoustic passive auto-mode-lock means,  optical mode-lock means comprising an optical ring resonator See figure 3.20

IPC Classes  ?

• H03B 17/00 - Generation of oscillations using a radiation source and a detector
• H10N 30/30 - Piezoelectric or electrostrictive devices with mechanical input and electrical output, e.g. functioning as generators or sensors
• G02F 1/365 - Non-linear optics in an optical waveguide structure
• H10N 30/87 - Electrodes or interconnections, e.g. leads or terminals
• G02F 1/21 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour by interference
• H10N 30/20 - Piezoelectric or electrostrictive devices with electrical input and mechanical output, e.g. functioning as actuators or vibrators
• H10N 30/85 - Piezoelectric or electrostrictive active materials

Abstract

The present invention relates to a method for preventing or treating cardiomyopathy due to energy failure in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a vector which comprises a nucleic acid sequence of a gene that can restore energy failure. More particularly, the invention relates to a method for preventing or treating a cardiomyopathy associated with Friedreich ataxia in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a vector which comprises a frataxin (FXN) encoding nucleic acid.

IPC Classes  ?

• C12N 15/86 - Viral vectors
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 38/44 - Oxidoreductases (1)
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

An installation is provided that is intended to separate two families of components of a mixture placed in a receptacle. The installation is provided with a screen and comprises a first electrode, a second electrode, and a generator that generates, between the first and second electrodes, an agitating alternating electrical field. The alternating electrical field is capable of alternately projecting all or some of the components of the mixture that is present in the receptacle towards or against the first electrode and then towards or against the second electrode in order to generate mechanical impacts on the components that contribute to breaking down the mixture within the receptacle and in order to facilitate the passage of components belonging to the second family through the screen. The screen ensures components belonging to the first family are retained in the receptacle.

IPC Classes  ?

• B03C 7/02 - Separators
• B03C 7/00 - Separating solids from solids by electrostatic effect
• B03C 7/06 - Separators with cylindrical material carriers

Abstract

The invention relates to a fluidic chip (101) comprising: - a first slide (100), the first slide (100) being made in a first material having an oxygen permeability of 10-9cm3(STP).cm.cm-2.s-1.cmHg-1or less at 25°C; - a second slide (104) comprising a channel (106), the second slide (104) being made in a second material having an oxygen permeability of 10-9cm3(STP).cm.cm-2.s-1.cmHg-1or less at 25°C; - a first adhesive layer (114) joining the first slide (100) to the second slide (104), the first adhesive layer (114) being made in a first adhesive composition having an oxygen permeability of 10-9cm3(STP).cm.cm-2.s-1.cmHg-1 or less at 25°C.

IPC Classes  ?

• C12M 3/06 - Tissue, human, animal or plant cell, or virus culture apparatus with filtration, ultrafiltration, inverse osmosis or dialysis means

Abstract

The present invention relates to antagonist of PDGF-AA protein, for use in the treatment of cancer. Here in the present invention, they show for the first time that targeting PDGF signaling through a ligand trap approach is able to inhibit tumor progression by the reprogramming the activation status of the CAFs (Cancer -Associated Fibroblasts). The inventors found that PDGF-AA bind directly on CD8+T cells by reducing their activation and cytotoxic properties. Furthermore, the use of neutralizing PDGF-AA antibodies in PDAC mouse model, reduced tumor growth by enhancing CD8+ T cell anti-tumoral response. Thus, neutralizing PDGF-AA which acts as a novel immunological check-point target in PDAC therefore allows to restore beneficial anti-tumor immunity in cancer, and especially in PDAC.

IPC Classes  ?

• C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
• A61P 35/00 - Antineoplastic agents
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum

Abstract

An electrolyte composition which comprises a non-aqueous organic solvent, a conducting electrolyte salt, and at least one additive of formula (I): wherein M is a metal, X is H or -O-R and R is an alkyl and an electrochemical device comprising the electrolyte composition.

IPC Classes  ?

• H01M 10/0567 - Liquid materials characterised by the additives
• H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries
• H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
• H01M 10/0568 - Liquid materials characterised by the solutes
• H01M 10/0569 - Liquid materials characterised by the solvents

Abstract

The invention relates to a hybrid source for generating pairs of entangled photons (30), the hybrid source (100) comprising: - at least one AlGaAs waveguide (10) comprising AlGaAs, the at least one AlGaAs waveguide (10) having a second order nonlinearity, - at least one Silicon-on-Insulator (SOI) platform (20) comprising at least one layer (4, 6, 8) comprising silicon and at least one silicon waveguide (2) comprising silicon, the at least one AlGaAs waveguide (10) comprising AlGaAs being arranged on the at least one SOI platform (20) such that the at least one AlGaAs waveguide (10) is evanescently coupled to the at least one silicon waveguide (2) in a coupling region, wherein pairs of entangled photons (30) generated in the at least one AlGaAs waveguide (10) upon optical pumping are coupled into the at least one silicon waveguide (2).

IPC Classes  ?

• G02F 1/365 - Non-linear optics in an optical waveguide structure

Abstract

The present invention relates to a treatment of Age-related diseases (ARDs). Here, the inventors identified the AP-1 family of transcription factors (TFs) as a novel actionable therapeutic target to reverse the senescence phenotype and to ameliorate age-related chronic lung and cardiac disease outcomes by repurposing a small molecule AP-1 inhibitor (APli) T- 5224. They demonstrated that AP-1 inhibition induces an improve of ARDs such as Emphysema, lung fibrosis or cardiac function. Other cardiac and pulmonary diseases could also benefit of this treatment. Thus, the present invention relates to an AP-1 inhibitor for use in the treatment of ARDs in subjects in need thereof.

IPC Classes  ?

• A61K 31/423 - Oxazoles condensed with carbocyclic rings
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 9/00 - Drugs for disorders of the cardiovascular system

Abstract

The present invention relates to a composite material comprising a porous solid support and at least one malonamide non-covalently bonded to the surface of this porous solid support. The present invention also relates to a process for preparing such a material and also to the use thereof for extracting and recovering palladium from an acid leaching solution containing same.

IPC Classes  ?

• B01J 20/22 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising organic material
• B01J 20/28 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof characterised by their form or physical properties
• B01J 20/32 - Impregnating or coating
• C22B 3/24 - Treatment or purification of solutions, e.g. obtained by leaching by physical processes, e.g. by filtration, by magnetic means by adsorption on solid substances, e.g. by extraction with solid resins
• C22B 11/00 - Obtaining noble metals

Abstract

A method for preventing or treating cardiomyopathy due to energy failure in a subject in need thereof is provided. The method comprises administering to the subject a therapeutically effective amount of a vector which comprises a nucleic acid sequence encoding a gene that can reverse energy failure. An exemplary cardiomyopathy is that which is associated with Friedreich ataxia and an exemplary nucleic acid sequence comprises a nucleic acid that encodes frataxin (FXN).

IPC Classes  ?

• C12N 15/86 - Viral vectors
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 38/44 - Oxidoreductases (1)
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

The present invention relates to an inhibitor of the interaction between the ROCK and PDK1 protein kinases. The present invention also relates to a pharmaceutical composition comprising at least one inhibitor of the interaction between the ROCK and PDK1 protein kinases as an active ingredient and at least one pharmaceutically acceptable excipient and/or support and/or a diluent and/or a pharmaceutically acceptable carrier. The invention also relates to the use of said pharmaceutical composition in the prevention and/or treatment of inflammatory diseases, viral and/or bacterial infections and autoimmune diseases.

IPC Classes  ?

• A61K 31/277 - NitrilesIsonitriles having a ring, e.g. verapamil
• A61K 31/415 - 1,2-Diazoles
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

This invention relates to a method for preparing a cyclic anhydride such as succinic anhydride and methyl succinic anhydride from an unsaturated carboxylic acid such as acrylic acid or crotonic acid. This method can also be used in the manufacture of food additives, plasticisers, polymers of interest, in particular polyurethanes and elastanes, resins, coatings and pharmaceutical products.

IPC Classes  ?

• C07D 307/60 - Two oxygen atoms, e.g. succinic anhydride
• B01J 31/04 - Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides containing carboxylic acids or their salts
• B01J 31/18 - Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes containing nitrogen, phosphorus, arsenic or antimony
• B01J 31/20 - Carbonyls
• B01J 31/24 - Phosphines

Abstract

A DC-to-DC converter for an electrical aircraft propulsion system designed to be connected in series with an electrical energy storage unit of the electrical propulsion system. The DC-to-DC converter includes an inverter, a transformer and a rectifier, and further includes a current source that is connected to the rectifier and is configured to control the power passing through the DC-to-DC converter. The transformer includes a primary and two secondaries, the two secondaries sharing a common terminal designed to be connected to a high-voltage DC bus of the electrical propulsion system and two other terminals that are connected to the rectifier. The rectifier includes two arms including at least two transistors that are each in series and are connected, on the one hand, to the two other terminals of the transformer and, on the other hand, to the current source.

IPC Classes  ?

• H02M 3/335 - Conversion of DC power input into DC power output with intermediate conversion into AC by static converters using discharge tubes with control electrode or semiconductor devices with control electrode to produce the intermediate AC using devices of a triode or a transistor type requiring continuous application of a control signal using semiconductor devices only
• B64D 27/33 - Hybrid electric aircraft
• B64D 27/35 - Arrangements for on-board electric energy production, distribution, recovery or storage
• H02J 7/00 - Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries
• H02M 1/34 - Snubber circuits
• H02M 1/44 - Circuits or arrangements for compensating for electromagnetic interference in converters or inverters

Abstract

A method for detecting biological objects by means of an SPR imaging detection system comprising an optical measurement device configured to generate plasmon resonance on a functionalized surface when said surface is exposed to a gas; the method comprising: an assimilation step by exposing the functionalized surface to a sample of interest formed of an aqueous carrier liquid containing the biological objects; a step of removing the liquid in contact with the functionalized surface and exposing the surface to a gas not containing the biological objects, said objects remaining bound to the ligands of the sensitive site of the functionalized surface; a step of acquiring an image of the sensitive site; a step of detecting the biological objects from the acquired image.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 21/552 - Attenuated total reflection

Abstract

The use, as gelling agent, of a compound having the general formula (I): in which: —Sacc represents a monosaccharide or polysaccharide comprising up to 20 sugar units, in pyranose and/or furanose form and of the L and/or D series, said monosaccharide or polysaccharide having at least one free hydroxyl function; —X1+ represents a cation chosen from the group consisting of: Na+, Li+, K+, +NR3R4R5R6, and R7—NH3, R3, R4, R5 and R6, which may be identical or different, representing a (C1-C20)alkyl group, R7 representing a (C1-C20)alkyl group, optionally including at least one unsaturation, said alkyl group being optionally substituted with at least one (C6-C10)aryl group, —R2 represents in particular H or methyl, and also the tautomeric forms thereof.

IPC Classes  ?

• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/06 - OintmentsBases therefor

Abstract

Process of grafting of a polyethylene-containing material to produce a modified polyethylene composition comprising providing a twin screw extruder with one or more thermal regulation devices; a polyethylene-containing material and a grafting agent and extruding the polyethylene-containing material and the grafting agent to obtain a modified polyethylene composition; the step of extruding comprises a thermal treatment of the polyethylene-containing material by self-heating of the material at a maximum barrel temperature Ts ranging from 315° C. to 410° C. in one or more hot zones of the extruder.

IPC Classes  ?

• C08F 255/02 - Macromolecular compounds obtained by polymerising monomers on to polymers of hydrocarbons as defined in group on to polymers of olefins having two or three carbon atoms
• B32B 1/08 - Tubular products
• B32B 15/085 - Layered products essentially comprising metal comprising metal as the main or only constituent of a layer, next to another layer of a specific substance of synthetic resin comprising polyolefins
• B32B 15/18 - Layered products essentially comprising metal comprising iron or steel
• B32B 15/20 - Layered products essentially comprising metal comprising aluminium or copper
• B32B 27/08 - Layered products essentially comprising synthetic resin as the main or only constituent of a layer next to another layer of a specific substance of synthetic resin of a different kind
• B32B 27/30 - Layered products essentially comprising synthetic resin comprising vinyl resinLayered products essentially comprising synthetic resin comprising acrylic resin
• B32B 27/32 - Layered products essentially comprising synthetic resin comprising polyolefins

Abstract

A component for a solid-oxide electrolyte fuel cell or electrolyser provided with an anticorrosion coating, as well as such a solid-oxide electrolyte fuel cell or electrolyser, the component including an electrically conductive substrate, and an anticorrosion coating deposited on at least one surface of the substrate, the anticorrosion coating including at least one main tantalum-nitride-based layer doped with one or more dopant elements chosen from the family of the transition metals or lanthanides.

IPC Classes  ?

• H01M 8/0228 - Composites in the form of layered or coated products
• H01M 8/0243 - Composites in the form of mixtures
• H01M 8/12 - Fuel cells with solid electrolytes operating at high temperature, e.g. with stabilised ZrO2 electrolyte
• H01M 8/1246 - Fuel cells with solid electrolytes operating at high temperature, e.g. with stabilised ZrO2 electrolyte characterised by the process of manufacturing or by the material of the electrolyte the electrolyte consisting of oxides

Abstract

The invention relates to a sputtering process of a target material in a vacuum environment comprising a sputtering target and plasmogenous process gas, wherein a transient electron accelerating pulse is applied to the sputtering target after plasma ignition, whereby applying said electron accelerating pulse involves applying a high negative bias voltage to the sputtering target during a period of time shorter than 1 microsecond, the bias voltage having an absolute value greater than 1 kV. This transitory regime of electron acceleration pulses is referred to as Fast High Voltage for lonization Improvement (FHiVI2). It can be operated alone or in combination with known sputtering processes, e.g. HiPIMS. The inventive process is suitable in sputtering deposition processes but also in other applications, e.g. for space propulsion.

IPC Classes  ?

• H01J 37/32 - Gas-filled discharge tubes
• F03H 1/00 - Use of plasma to produce a reactive propulsive thrust
• H01J 37/34 - Gas-filled discharge tubes operating with cathodic sputtering
• H05H 1/54 - Plasma accelerators

Abstract

uixxxxsMspsppp. The single or multiple scattering rate is a local physical characteristic representative of the local nature of the medium.

IPC Classes  ?

• G01S 7/52 - Details of systems according to groups , , of systems according to group
• G01N 29/26 - Arrangements for orientation or scanning
• G01S 15/89 - Sonar systems specially adapted for specific applications for mapping or imaging

Abstract

The present invention relates to a device for training a generative model configured to generate at least one synthetic 3D representation of myelin content and to a device and a computer-implemented method for obtaining at least one synthetic 3D image representative of myelin content for a patient using a trained generative model having training parameters obtained using the device for training.

IPC Classes  ?

• G06T 7/00 - Image analysis
• G06T 7/11 - Region-based segmentation

Abstract

The invention concerns a test cell for an EQCM of an electrochemical system comprising a liquid electrolyte. It comprises: - a cell body (10) comprising an electrolyte cavity (11), a quartz resonator (12) coated with a first working electrode (FW) with an active material to be tested and being configured to provide a signal function of a mass variation of the first working electrode (FW), - a cell basis (20) comprising a connecting terminal (22) receiving the signal from the quartz resonator (12), The test cell (8) also comprises a cell holder (30), comprising: - a second electrolyte cavity connecting with the first electrolyte cavity, - a second working electrode, connected to the quartz resonator through the first and second electrolyte cavity (11), comprising similar material to the active material to be tested, - a counter electrode connected to the quartz resonator through the first and second electrolyte cavities (11).

IPC Classes  ?

• G01N 29/02 - Analysing fluids
• G01N 29/036 - Analysing fluids by measuring frequency or resonance of acoustic waves
• G01N 29/22 - Investigating or analysing materials by the use of ultrasonic, sonic or infrasonic wavesVisualisation of the interior of objects by transmitting ultrasonic or sonic waves through the object Details
• H01M 10/52 - Removing gases inside the secondary cell, e.g. by absorption

Abstract

The invention relates to the combination of a βig-h3 antagonist and a PDGF-AA antagonist, for use in the prevention or treatment of a patient affected with cancer disease. In particular, the combination restore CD8+ T cell activation and thus anti-tumoral cytotoxic response. The cancer may be pancreatic ductal adenocarcinoma. PDGF-AA antagonist may be an anti-PDGF-AA neutralizing antibody or aptamer. Said βig-h3 antagonist may be an anti-βig-h3 neutralizing antibody or aptamer. The cancer is more particularly a cancer associated with a stroma expressing/secreting PDGF-AA and βig-h3. The invention also relates to methods of treatment of cancer disease with said combination.

IPC Classes  ?

• C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans

Abstract

The invention relates to a circuit (1), comprising an input line (2), an output line (3), and a main switched-mode converter (4) that has an input connected to the input line and an output connected to the output line and produces operating harmonics, the circuit comprising at least one additional DC/AC converter (5) mounted in parallel with the main converter and arranged to inject, onto the one of the two lines that carries the sine-wave signal and in synchronisation with the sine wave, an additional signal depending on the operating harmonics of the main converter, the additional converter comprising at least one switching stage (7) consisting of a broadband semiconductor.

IPC Classes  ?

• H02P 9/48 - Arrangements for obtaining a constant output value at varying speed of the generator, e.g. on vehicle
• H02M 7/81 - Conversion of AC power input into DC power outputConversion of DC power input into AC power output with possibility of reversal by static converters using discharge tubes with control electrode or semiconductor devices with control electrode using devices of a triode or transistor type requiring continuous application of a control signal arranged for operation in parallel
• H02J 3/01 - Arrangements for reducing harmonics or ripples
• H02M 1/12 - Arrangements for reducing harmonics from AC input or output
• H02M 7/217 - Conversion of AC power input into DC power output without possibility of reversal by static converters using discharge tubes with control electrode or semiconductor devices with control electrode using devices of a triode or transistor type requiring continuous application of a control signal using semiconductor devices only

Abstract

Jam-3Jam-3Jam-3-deficiency rewired the transcriptional program of leukemia initiating cells (LIC) with upregulation of genes belonging to AP-l/TNF-α pathways. Transposition of results to human allowed to determine a new prognosis score called ATIC for AP-l/TNF-α Initiating Cells, complementary and distinct from the LSC17 score. Thus, the invention relates to a method for predicting the survival time of a patient suffering from an Acute Myeloid Leukemia (AML) based on the determination in a sample obtained from the patient of the expression levels of at least 7 genes selected in the group consisting in: JAM3, DUSP1, JUN, IER2, DUSP2, RGS1, H2BC8, PTGS2, NFKBID, PPP1R15A, NFKBIZ, ZFP36, SNORA28, TPT1, KLF2, BTG2, JUNB, JUNE), ATF3, UBC, SKIL, TAF7, SLFN12L, NR4A1, CHST2, GASS, SNORA31, HES1, EGR3, RPS13, PMAIP1, RHOB, MYL9, ZNF699, ZNF101, FOS, FJX1, RPP25L, HEY1, PTMA, GIMAP4, EFCAB11, FOSE, CD14, CCL4, CCL3, PF4, OSM, CD69, ITGA2B, VWF, MYCN and F2RL2.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The present invention concerns at least one modulator of the metabolism and/or mitochondrial activity, in particular at least one inhibitor of the OXPHOS mitochondrial electron transport chain and/or inhibitor of the MVA pathway, for use for the prevention and/or treatment of neurofibroma. Combination of such modulators, in particular of an inhibitor of the OXPHOS mitochondrial electron transport chain with an inhibitor of the MVA pathway, as well as pharmaceutical compositions comprising them are also contemplated.

IPC Classes  ?

• A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
• A61K 31/22 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• A61K 31/404 - Indoles, e.g. pindolol
• A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
• A61K 31/451 - Non-condensed piperidines, e.g. piperocaine having a carbocyclic ring directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
• A61K 31/47 - QuinolinesIsoquinolines
• A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents

Abstract

The present application relates to a process for preparing cyclic organopolysiloxane OC by depolymerization of at least one organopolysiloxane O selected from: - linear organopolysiloxanes, - branched organopolysiloxanes, - crosslinked organopolysiloxanes, or mixtures thereof; in the presence of a solvent, catalyzed by an alkali salt SA selected from alkali silanolates, alkali siliconates, or mixtures thereof, in which the amount of alkali salt used is between 0.01 and 2% by weight relative to the weight of organopolysiloxane O.

IPC Classes  ?

• C08G 77/04 - Polysiloxanes
• C08J 11/22 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation by treatment with organic material by treatment with organic oxygen-containing compounds

Abstract

A device for simulating a biological barrier comprising a multi-well plate covered by a port plate and sustained by a connection plate ensuring connection to a biochip.

IPC Classes  ?

• C12M 1/32 - Inoculator or sampler multiple field or continuous type
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means
• C12M 1/42 - Apparatus for the treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic wave

Abstract

A device for interfacing a biochip.

IPC Classes  ?

• C12M 3/06 - Tissue, human, animal or plant cell, or virus culture apparatus with filtration, ultrafiltration, inverse osmosis or dialysis means
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers

Abstract

The present invention relates to isolated single domain antibodies having specificity for deNEDDylating enzyme NEDP1. It concerns in particular to a kit for inhibiting the deNEDDylating enzyme NEDP1, more particularly for the prevention and/or treatment of neurodegenerative diseases such as Amyotrophic Lateral Sclerosis and/or Frontotemporal Degeneration, said kit comprising at least one isolated single domain antibody specific for the deNEDDylating enzyme NEDP1. It further relates to said isolated single domain antibodies for use as inhibitors of the deNEDDylating enzyme NEDP1, in particular for the prevention and/or treatment of neurodegenerative diseases such as ALS/FTD.

IPC Classes  ?

• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

A ready-mix concrete or mortar, or precast concrete composition has at least one aggregate (A), a binder composition (B), at least one alkali sulfate activator (C), water (D) and at least one water reducing polymer (E). The binder composition includes ground blast furnace slag and one or more optional components being at least one hydraulic binder other than slag, one or more supplementary cementitious materials, and one or more filler materials. The water reducing polymer (E) is a copolymer comprising the following monomeric units, a monomeric unit A between 0 and 40, a monomeric unit B between 25 and 95, a monomeric unit C between 5 and 50, and a monomeric unit D between 0 and 25, the values being in mol %. The ready-mix concrete or mortar, or precast concrete composition is classified in one of the classes S3, S4 and S5 according to standard NF EN 206.

IPC Classes  ?

• C04B 24/26 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds
• C04B 24/16 - Sulfur-containing compounds
• C04B 24/24 - Macromolecular compounds
• C04B 28/08 - Slag cements
• C04B 103/30 - Water reducers, plasticisers, air-entrainers

Abstract

A process for preparing a sunflower seed protein isolate and a protein isolate which is obtainable by such process. The process comprises the following steps: mixing a defatted seed meal with an aqueous NaCl solution at a basic pH; separating said solubilised protein solution from solids; diafiltering said solubilised protein solution through an ultrafiltration membrane system using an aqueous NaCl diafiltration NaCl solution and at least 2 diavolumes of said aqueous NaCl diafiltration solution, diafiltering said NaCl-diafiltered protein; concentrating said purified protein solution; and drying said purified protein concentrate to obtain a protein isolate.

IPC Classes  ?

• A23J 1/14 - Obtaining protein compositions for foodstuffsBulk opening of eggs and separation of yolks from whites from leguminous or other vegetable seedsObtaining protein compositions for foodstuffsBulk opening of eggs and separation of yolks from whites from press-cake or oil-bearing seeds
• A23L 33/185 - Vegetable proteins
• B01D 61/14 - UltrafiltrationMicrofiltration
• B01D 61/16 - Feed pretreatment
• C07K 14/415 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from plants

Abstract

A method of treating an inflammatory disease selected from the group of atherosclerosis, ankylosing spondylitis, and Sjogren syndrome. The method includes administering a quinoline derivative to a patient in need thereof. The quinoline derivative is a compound of formula (I) A method of treating an inflammatory disease selected from the group of atherosclerosis, ankylosing spondylitis, and Sjogren syndrome. The method includes administering a quinoline derivative to a patient in need thereof. The quinoline derivative is a compound of formula (I) A method of treating an inflammatory disease selected from the group of atherosclerosis, ankylosing spondylitis, and Sjogren syndrome. The method includes administering a quinoline derivative to a patient in need thereof. The quinoline derivative is a compound of formula (I) or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

• C07D 215/38 - Nitrogen atoms
• A61K 31/47 - QuinolinesIsoquinolines
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The invention relates to an isolated polynucleotide comprising a sequence having at least 90% sequence identity with sequence GGXaGGCAXbXcCCXdXeGGAAAGG (SEQ ID NO 1), wherein Xa, Xb, Xc, Xd and Xe are independently T or U, and its use in the treatment of Prader-Willi Syndrome and/or Prader Willi-like syndromes. The invention also relates to pharmaceutical compositions an isolated polynucleotide comprising a sequence having at least 90% sequence identity with sequence GGXaGGCAXbXcCCXdXeGGAAAGG (SEQ ID NO 1), wherein Xa, Xb, Xc, Xd and Xe are independently T or U and its use in the prevention and/or treatment of Prader-Willi Syndrome and/or Prader Willi-like syndromes. The present invention finds applications in the therapeutic and diagnostic medical technical fields.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 25/00 - Drugs for disorders of the nervous system
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The invention relates to a method for assembling at least two parts, the method comprising the following steps: - preparing a first element (4) comprising a first surface (8) having a general shape provided with a cavity (6); - preparing a second element (14) having a main surface (16) that has the same shape as at least one portion of the general shape of the first surface (8) of the first element (4); - applying a coating (26) to the first surface (8) of the first element (4) and to the main surface (16) of the second element (14); - placing the second element (14) on the first surface (8) of the first element (4) so that it fully covers the cavity (6); - placing the first element (4) and the second element (14) in a chamber (28) containing a fluid (30); and - pressurising the fluid (30) contained in the chamber (28).

IPC Classes  ?

• B81C 3/00 - Assembling of devices or systems from individually processed components
• H01L 23/473 - Arrangements for cooling, heating, ventilating or temperature compensation involving the transfer of heat by flowing fluids by flowing liquids
• H01L 21/48 - Manufacture or treatment of parts, e.g. containers, prior to assembly of the devices, using processes not provided for in a single one of the groups or

Abstract

The invention relates to a process for synthesis of a benzophenone or a benzophenone derivative which uses a metal base with a solvent selected from linear or cyclic carboxamides for activating a compound of formula (II) and allowing it to be coupled with a compound of formula (I) so as to give said benzophenone or said benzophenone derivative.

IPC Classes  ?

• C07C 45/45 - Preparation of compounds having C=O groups bound only to carbon or hydrogen atomsPreparation of chelates of such compounds by condensation
• C07D 213/50 - Ketonic radicals
• C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07C 45/46 - Friedel-Crafts reactions
• C07D 317/54 - Radicals substituted by oxygen atoms

Abstract

The invention relates to a method, implemented by a control system, for controlling cell production in a bioreactor. The bioreactor comprises a cell culture vessel containing a culture medium and microcarriers, on the surface of which the cells grow. The method comprises dynamic adjustment of parameters during production. The dynamically-adjusted parameters include at least a temperature of the culture medium, a pH of the culture medium, a concentration of oxygen dissolved in the culture medium, and a quantity of microcarriers present in the vessel. The method improves the quality and quantity of the biomass produced in the bioreactor.

IPC Classes  ?

• C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means
• C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters
• C12M 1/36 - Apparatus for enzymology or microbiology including condition or time responsive control, e.g. automatically controlled fermentors

Abstract

The present invention relates to a method for extracting natural sea urchin pigments in a novel form (referred to as pigment matrix), to this pigment matrix and to the use thereof as a natural dye.

IPC Classes  ?

• C09B 61/00 - Dyes of natural origin prepared from natural sources

Abstract

The present invention relates to a method for identifying the types and/or subtypes of viral particles and/or extracellular vesicles using nanoporous membranes coupled with optical detection. The invention also relates to the use of this method, in particular for identifying/naming the type and/or subtypes of viral particles and/or extracellular vesicles present in a biological sample. More specifically, transporting viral particles and extracellular vesicles through nanopores allows the type of particle to be identified through its specific interaction with the nanopore and the modelling of this phenomenon, particularly using a bottleneck model.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances

Abstract

The present invention relates to antibodies and compositions that can be used to treat candidiasis.

IPC Classes  ?

• C07K 16/14 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from fungi, algae or lichens

Abstract

122 are as defined herein, or a pharmaceutically acceptable salt or solvate thereof, where said compounds of formula (I) are 3,5-dialkoxypyridine (DARQ) analogues of bedaquiline (BDQ) and may be used in the treatment of a nontuberculous mycobacterial (NTM) infection.

IPC Classes  ?

• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61P 31/04 - Antibacterial agents
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Method for imaging vascular activity dynamically at a microscopic scale in a vascular network of a human or animal, the method including: (a) performing a temporal series of Ultrasound Localization Microscopy images of a region of the vascular network, to obtain values of a vascular dynamics parameter in an area of interest in the region, a recording period of the temporal series of ULM images corresponding to a dynamical event, due to a cause other than cardiac pulsatily, which activates the vascular network in the region; (b) computing, based on the values of the vascular dynamics parameter, a measure of an evolution of the vascular dynamics parameter in response to the dynamical event.

IPC Classes  ?

• A61B 8/08 - Clinical applications
• A61B 8/00 - Diagnosis using ultrasonic, sonic or infrasonic waves
• A61B 8/04 - Measuring blood pressure
• A61B 8/06 - Measuring blood flow

Abstract

The present invention relates to a multilayer material, comprising a solid substrate coated at least partially with a textured α-quartz buffer layer, the crystallographic direction of the α-quartz being parallel to the crystallographic direction of the silicon; and on said α-quartz buffer layer, a layer of one-dimensional epitaxial ZnO microcrystals (or epitaxial ZnO microwires), said microcrystals being self-assembled. The present invention also relates to a method for producing such a multilayer material, as well as to the industrial use thereof in various technical fields.

IPC Classes  ?

• C30B 29/62 - Whiskers or needles
• C30B 5/00 - Single-crystal growth from gels
• C30B 7/00 - Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
• C30B 7/10 - Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions by application of pressure, e.g. hydrothermal processes
• C30B 7/14 - Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions the crystallising materials being formed by chemical reactions in the solution
• C30B 29/16 - Oxides
• H03H 9/17 - Constructional features of resonators consisting of piezoelectric or electrostrictive material having a single resonator
• H03H 9/19 - Constructional features of resonators consisting of piezoelectric or electrostrictive material having a single resonator consisting of quartz

Abstract

The invention relates to a method for monitoring at least one substance which may be produced or consumed by at least one living entity, and to an assembly for implementing the method. The method comprises flowing liquid medium having a controlled concentration of a dissolved gas and a controlled flow rate to a culture system and taking at least one measurement within the culture system so as to determine the presence, concentration or amount of the at least one substance in the liquid medium in the culture system; and/or taking at least a first measurement upstream of the culture system and a second measurement downstream of the culture system, and determining a concentration or amount of the substance consumed or produced by the at least one living entity based on the difference between the second measurement and the first measurement.

IPC Classes  ?

• C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters

Abstract

The present invention relates to a process for preparing a crosslinked polymer composition containing exchangeable pending links and exchangeable crosslinks, by boronic ester metathesis reactions, said process implementing a thermoplastic polymer comprising pending boronic ester groups, and an additive as crosslinking agent that melts, and thus crosslinks, in the polymer matrix at a temperature, called temperature of dissociation, higher that the processing temperature. Said temperature of dissociation is reached in the later curing step only.

IPC Classes  ?

• C08F 8/42 - Introducing metal atoms or metal-containing groups

Abstract

The application relates to a method for protecting a microgrid from a voltage drop or sag occurring in a main grid connected to said microgrid, the method comprising the following steps: a. supplying (105) power to the microgrid through the main grid; b. ascertaining that the voltage drop or sag is occurring in the main grid by executing the following steps: i. measuring (110) an instantaneous output voltage; ii. comparing (130) the measured instantaneous output voltage with a reference instantaneous output voltage; iii. Incrementing (140) a counter when the measured instantaneous output voltage differs from the reference instantaneous output voltage by more than a voltage threshold; and iv. ascertaining (150) that the voltage drop or sag is occurring in the main grid when the counter holds a value that exceeds a counter threshold; and c. disconnecting the microgrid from the main grid when the voltage drop or sag occurring in the main grid has been ascertained.

IPC Classes  ?

• H02J 3/38 - Arrangements for parallelly feeding a single network by two or more generators, converters or transformers
• H02J 3/00 - Circuit arrangements for ac mains or ac distribution networks

Abstract

The application relates to a method for controlling a microgrid (10) comprising the steps of: maintaining a switching device (60) connecting two busbars (30, 40) of the microgrid (10) and a circuit breaker (20) connecting the microgrid (10) to a utility grid (100) closed, the microgrid (10) being operated in a grid connected mode; measuring (202) a voltage present in the microgrid (10); determining (205) if the measured voltage corresponds to a loss of voltage or a fault in the microgrid (10); and if a the loss of voltage or fault is detected in the microgrid (10), opening (210) the switching device (60), the critical loads being supplied by the battery energy storage system (50) and the circuit breaker (20) remaining closed during (215) at least a fault ride through period.

IPC Classes  ?

• H02J 3/00 - Circuit arrangements for ac mains or ac distribution networks
• H02J 3/38 - Arrangements for parallelly feeding a single network by two or more generators, converters or transformers

Abstract

A component for an acid electrolyte fuel cell or electrolyser provided with an anticorrosion coating, as well as such an acid electrolyte fuel cell or electrolyser, the component including an electrically conductive substrate, and an anticorrosion coating deposited on at least one surface of the substrate, the anticorrosion coating including at least one main tantalum-nitride-based layer doped with one or more dopant elements chosen from the family of the transition metals or lanthanides.

IPC Classes  ?

• H01M 8/0228 - Composites in the form of layered or coated products
• C25B 9/60 - Constructional parts of cells
• H01M 8/0243 - Composites in the form of mixtures
• H01M 8/086 - Phosphoric acid fuel cells [PAFC]
• H01M 8/10 - Fuel cells with solid electrolytes
• H01M 8/1018 - Polymeric electrolyte materials

Abstract

xy2z∞233 -33 2-33H-, and –Cl and optionally also substituted at least once by -COO-; where y is 1 to 3; and where z is 0 to 10.

IPC Classes  ?

• G01K 3/04 - Thermometers giving results other than momentary value of temperature giving mean valuesThermometers giving results other than momentary value of temperature giving integrated values in respect of time
• C09K 11/02 - Use of particular materials as binders, particle coatings or suspension media therefor
• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials
• G01K 11/20 - Measuring temperature based on physical or chemical changes not covered by group , , , or using thermoluminescent materials